To investigate the role of new serologic biomarkers in therapy monitoring and to determine their potential prognostic significance in ovarian cancer, TIMP-1, VEGF-165 and CA-125 were analyzed in 148 serum samples from 37 patients with epithelial ovarian cancer. The gene discussed is TIMP1; the disease is ovarian carcinoma.